| Inhibiting the NLRP3 inflammasome LY El-Sharkawy, D Brough, S Freeman Molecules 25 (23), 5533, 2020 | 97 | 2020 |
| LRRC8A is essential for hypotonicity-, but not for DAMP-induced NLRP3 inflammasome activation JP Green, T Swanton, LV Morris, LY El-Sharkawy, J Cook, S Yu, ... Elife 9, e59704, 2020 | 42 | 2020 |
| Discovery of an inhibitor of DNA-driven inflammation that preferentially targets the AIM2 inflammasome JP Green, LY El-Sharkawy, S Roth, J Zhu, J Cao, AG Leach, A Liesz, ... Iscience 26 (5), 2023 | 18 | 2023 |
| Selective inhibition of the K+ efflux sensitive NLRP3 pathway by Cl− channel modulation T Swanton, JA Beswick, H Hammadi, L Morris, D Williams, S De Cesco, ... Chemical Science 11 (43), 11720-11728, 2020 | 17 | 2020 |
| Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors LY El‐Sharkawy, RA El‐Sakhawy, M Abdel‐Halim, K Lee, GA Piazza, ... Archiv der Pharmazie 351 (5), 1800018, 2018 | 15 | 2018 |
| Synthesis of novel 1, 2-diarylpyrazolidin-3-one–based compounds and their evaluation as broad spectrum antibacterial agents SA Mokbel, RK Fathalla, LY El-Sharkawy, AH Abadi, M Engel, ... Bioorganic Chemistry 99, 103759, 2020 | 11 | 2020 |
| Computational evaluation of Azadirachta indica-derived bioactive compounds as potential inhibitors of NLRP3 in the treatment of Alzheimer’s disease FO Ishabiyi, JO Ogidi, BA Olukade, CC Amorha, LY El-Sharkawy, ... Journal of Alzheimer's Disease 94 (s1), S67-S85, 2023 | 3 | 2023 |
| Discovery of an AIM2 inflammasome inhibitor for the treatment of DNA-driven inflammatory disease JP Green, LY El-Sharkawy, S Roth, J Zhu, J Cao, AG Leach, A Liesz, ... bioRxiv, 2022.07. 28.501942, 2022 | 2 | 2022 |
| Inhibiting the Inflammasomes L El-Sharkawy University of Manchester, 2022 | | 2022 |
